Canadians warn patients against Avandia

More limits on Avandia use, this time from Canadian regulators. While the FDA continues to debate adding various warnings to GlaxoSmithKline's embattled diabetes drug, HealthCanada has induced GSK to release new, restrictive guidelines.

According to GSK's Dear Doctor letter, the drug should never be used in a patient with heart failure, not even in the early stages. The drug can be added to metformin treatment, but only if metformin alone doesn't work. And Avandia should only be used on its own or with sulfa drugs if the patient can't tolerate metformin or has tried metformin without success. And it shouldn't be taken with insulin.

- see the "Dear Health Care Professional" letter at HealthCanada
- check out this item at Pharmalot
- read the report from The Record

Related Articles:
Avandia cleared FDA by one vote. Report
GSK plant closure begins 5,000 job cuts. Report
Teva inks deal to sell generic Avandia. Report
Avandia, Actos don't boost death risk. Report
FDA adds to drumbeat of bad news for Avandia. Report
Expert committee says Avandia should stay. Report

Suggested Articles

Eli Lilly and Boehringer's Jardiance fell short in a heart failure trial in patients with or without diabetes—a test AZ's rival Farxiga recently aced.

There's a lot at stake in the world of pharma litigation, and in two cases involving J&J and Gilead, attorney misconduct allegations have come up.

Without any new data, Sarepta appealed an FDA rejection and got a surprising nod for Vyondys 53—its second med approved on a surrogate marker.